These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8570868)

  • 1. Endothelin in patients with chronic renal failure.
    Nĕmecek K; Bártová V; Jáchymová M; Horký K
    Ren Fail; 1995 Sep; 17(5):559-63. PubMed ID: 8570868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endothelin in patients with chronic kidney failure].
    Nĕmecek K; Bártová V; Jáchymová M; Horký K
    Cas Lek Cesk; 1995 Aug; 134(16):511-3. PubMed ID: 7553749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.
    Stefanidis I; Mertens PR; Wurth P; Bach R; Makropoulos W; Mann H; Heintz B
    Int J Artif Organs; 2001 Jun; 24(6):367-73. PubMed ID: 11482502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
    Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
    Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of erythropoietin on glucose tolerance in hemodialysis patients.
    Chagnac A; Weinstein T; Zevin D; Korzets A; Hirsh J; Gafter U; Levi J
    Clin Nephrol; 1994 Dec; 42(6):398-400. PubMed ID: 7882604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients.
    Samtleben W; Baldamus CA; Bommer J; Grützmacher P; Nonnast-Daniel B; Scigalla P; Gurland HJ
    Contrib Nephrol; 1989; 76():193-200; discussion 212-8. PubMed ID: 2684521
    [No Abstract]   [Full Text] [Related]  

  • 10. Endothelin in chronic renal failure.
    Takahashi K; Totsune K; Mouri T
    Nephron; 1994; 66(4):373-9. PubMed ID: 8015637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis.
    Grandaliano G; Teutonico A; Allegretti A; Losappio R; Mancini A; Gesualdo L; Schena FP; Pertosa G
    Kidney Int; 2003 Aug; 64(2):715-9. PubMed ID: 12846770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    J Am Soc Nephrol; 1994 Apr; 4(10):1809-13. PubMed ID: 8068879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin.
    Schiffl H
    Int J Artif Organs; 1992 Jun; 15(6):343-8. PubMed ID: 1639525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.